Funding in, findings out
For any dataset: the NCI award that paid to create it, and the awards that got a published finding out of it afterwards.
ORGANOID-PANCREATIC
Pancreas Cancer Organoid Profiling
13 awards paid to create it · 49 awards funded work that used it
1. Awards that paid to create this data (6 of 13)
- Developmental Research Program · Michael A. Hollingsworth, JULIA A BRIDGE · FY2008–2018
- Exploring Glycobiology and Discovering Biomarkers for Pancreatic Cancer · Dannielle Engle · FY2019–2021
- Mutant mouse models of exocrine pancreatic cancer · David A Tuveson · FY2004–2008
- Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response · David A Tuveson · FY2017–2021
- (PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer · David A Tuveson · FY2014–2017
- Pharmacogenomic and circulating tumor cell approach to individualized treatment… · Brian J. McCarthy, Kenneth H. Yu · FY2016–2020
The best connected are shown.
2. The dataset
3. Articles that used it (4)
- Hezaveh et al. · Immunity · 2022594 citations
- Loveless et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · 202559 citations
- Duan et al. · Translational oncology · 201918 citations
- Ventre et al. · Journal of immunology (Baltimore, Md. : 1950) · 202315 citations
4. Awards those articles were funded by (6 of 49)
- Research Program: Molecular and Cellular Oncogenesis · Maureen E. Murphy, Luis J Montaner · FY1985–2026funded 1 of these 4 articles
- The role of marginal zone macrophages and immuno-metabolism in tumor-driven MDS… · Tracy L McGaha · FY2015–2020funded 1 of these 4 articles
- Mechanistic investigations of microbiome-driven aryl hydrocarbon receptor activ… · Tracy L McGaha · FY2021–2025funded 1 of these 4 articles
- Understanding the Fate of Metaplastic Tuft Cells in the Progression of Pancreat… · Daniel James Salas-Escabillas · FY2022–2024funded 1 of these 4 articles
- Investigation of Immunotherapy-induced Alterations to Cellular Communication Ne… · Jacob Thomas Mitchell · FY2024funded 1 of these 4 articles
- Identification of resistance mechanisms to direct KRAS inhibition in pancreatic… · Andrew M Waters · FY2023–2025funded 1 of these 4 articles
The best connected are shown.
Direct evidence: the award is on the paper, or the accession is in the articleWeaker: infrastructure support, or use declared but not shownHover any card to follow its chain
Awards that paid to create this data
Credited on the dataset's own marker paper.
| Award | Project | Evidence |
|---|---|---|
| P50CA127297 P50FY2008–2018$34.0M | Developmental Research Program | API2 |
| R00CA204725 R00FY2019–2021$747k | Exploring Glycobiology and Discovering Biomarkers for Pancreatic Cancer | API2 |
| R01CA101973 R01FY2004–2008$1.3M | Mutant mouse models of exocrine pancreatic cancer | API |
| R01CA188134 R01FY2017–2021$3.0M | Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response | API2 |
| R01CA190092 R01FY2014–2017$2.2M | (PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer | API2 |
| R01CA202762 R01FY2016–2020$2.8M | Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer | API2 |
| R01CA212600 R01FY2017–2021$1.9M | Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer | API2 |
| R50CA211462 R50FY2016–2026$1.4M | Critical Resources Provided by UNMC Rapid Autopsy Program (RAP) Biorepository Stimulate Cancer Research | API2 |
| T32CA148056 T32FY2011–2020$1.8M | CSHL Cancer Gene Discovery and Cancer Biology Postdoctoral Research Training Program | API2 |
| U01CA168409 U01FY2012–2016$7.3M | COMPUTATIONAL AND FUNCTIONAL APPROACHES TO VALIDATING CANCER GENOME TARGETS | API2 |
| U01CA210240 U01FY2017–2026$12.9M | Pancreatic Cancer Detection Consortium | API2 |
| U01CA224013 U01FY2018–2022$4.2M | CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor Heterogeneity | API2 |
| U10CA180944 U10FY2014–2018$2.0M | Integrated Translational Cancer Science Center | API2 |
Awards that funded work using this data
4 of 10 traced articles report an NCI award. 12 of these awards also paid to create the data - the same team publishing again on its own cohort, not a duplicated row.
| Award | Project | Articles it is credited on | Evidence |
|---|---|---|---|
| P30CA010815 P30FY1985–2026$173.4M | Research Program: Molecular and Cellular Oncogenesis | API | |
| R01CA190449 R01FY2015–2020$1.3M | The role of marginal zone macrophages and immuno-metabolism in tumor-driven MDSC development | API | |
| R01CA255670 R01FY2021–2025$1.8M | Mechanistic investigations of microbiome-driven aryl hydrocarbon receptor activity and macrophage function in pancreatic cancer. | API | |
| F31CA271576 F31FY2022–2024$93k | Understanding the Fate of Metaplastic Tuft Cells in the Progression of Pancreatic Cancer | API | |
| F31CA284525 F31FY2024$42k | Investigation of Immunotherapy-induced Alterations to Cellular Communication Networks in Pancreatic Ductal Adenocarcinoma | API | |
| K22CA276632 K22FY2023–2025$576k | Identification of resistance mechanisms to direct KRAS inhibition in pancreatic cancer | API | |
| K99CA204725 K99FY2016–2017$256k | Exploring Glycobiology and Discovering Biomarkers for Pancreatic Cancer | API | |
| P01CA013106 P01FY1985–2026$269.1M | Project 2: Splicing Dysregulation in Cancer | API | |
| P20CA101955 P20FY2003–2007$4.6M | SPORE in Pancreatic Cancer | API | |
| P20CA192994 P20FY2015–2018$2.7M | 1/2: Partnership to study racial/ethnic differences in GI cancer biology | API | |
| P20CA192996 P20FY2015–2018$1.1M | 2/2 Partnership to Study Racial/Ethnic Differences in GI Cancer Biology | API | |
| P30CA013696 P30FY1985–2026$280.8M | Developmental Funds | API | |
| P30CA034196 P30FY1985–2026$123.6M | Cancer Center Support (CORE) Grant | API | |
| P30CA045508 P30FY1987–2026$227.8M | Cancer Research Training and Education Coordination Core | API | |
| P30CA046592 P30FY1988–2026$317.9M | Cancer Center Administration | API | |
| P50CA101955 P50FY2010–2014$22.2M | UAB / UMN SPORE in Pancreatic Cancer | API | |
| P50CA127297 P50FY2008–2018$34.0M | Developmental Research Program | API2 | |
| R00CA204725 R00FY2019–2021$747k | Exploring Glycobiology and Discovering Biomarkers for Pancreatic Cancer | API2 | |
| R00CA263154 R00FY2022–2024$862k | Investigating Cellular Communication in the Tumor Microenvironment in Pancreatic Cancer | API | |
| R01CA151588 R01FY2010–2020$3.3M | Mechanisms of Pancreatic Inflammation, Tissue Repair and Carcinogenesis | API | |
| R01CA182076 R01FY2014–2026$3.6M | Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas | API | |
| R01CA188134 R01FY2017–2021$3.0M | Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response | API2 | |
| R01CA190092 R01FY2014–2017$2.2M | (PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer | API2 | |
| R01CA198074 R01FY2015–2019$1.9M | Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer | API | |
| R01CA202762 R01FY2016–2020$2.8M | Pharmacogenomic and circulating tumor cell approach to individualized treatment of pancreatic cancer | API2 | |
| R01CA212600 R01FY2017–2021$1.9M | Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer | API2 | |
| R01CA244931 R01FY2020–2024$1.9M | Targeting metabolic stress to induce pancreatic tumor cell death | API | |
| R01CA247516 R01FY2020–2024$2.3M | Metaplastic Tuft Cells in Pancreatic Cancer | API | |
| R01CA248160 R01FY2020–2024$2.0M | Stromal metabolism promotes therapeutic resistance in pancreatic cancer | API | |
| R01CA281198 R01FY2024–2026$1.9M | Collagen Signaling in Pancreatic Cancer | API | |
| R33CA206949 R33FY2016–2019$1.6M | Advanced Development and Validation of 3 Dimensional Spheroid Culture of Primary Cancer Cells using Nano3D Technology | API | |
| R35CA197745 R35FY2015–2026$11.5M | Predicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell Level | API | |
| R50CA211462 R50FY2016–2026$1.4M | Critical Resources Provided by UNMC Rapid Autopsy Program (RAP) Biorepository Stimulate Cancer Research | API2 | |
| R50CA211506 R50FY2016–2025$2.1M | Preclinical Models for Cancer Therapeutic Development | API | |
| T32CA148056 T32FY2011–2020$1.8M | CSHL Cancer Gene Discovery and Cancer Biology Postdoctoral Research Training Program | API2 | |
| U01CA168409 U01FY2012–2016$7.3M | COMPUTATIONAL AND FUNCTIONAL APPROACHES TO VALIDATING CANCER GENOME TARGETS | API2 | |
| U01CA200468 U01FY2016–2026$11.0M | Clinical Validation Center for Early Detection of Pancreatic Cancer | API | |
| U01CA210240 U01FY2017–2026$12.9M | Pancreatic Cancer Detection Consortium | API2 | |
| U01CA224013 U01FY2018–2022$4.2M | CSHL-JAX Patient-Derived Models of Pancreatic Cancer as Systems for Investigating Tumor Heterogeneity | API2 | |
| U01CA224145 U01FY2017–2021$2.6M | Interrupting Cellular Crosstalk in the Immunosuppressive Microenvironment of Pancreas Cancer | API | |
| U01CA274154 U01FY2022–2026$4.2M | Fibroblast orchestration of the immune response in pancreatic cancer | API | |
| U10CA180944 U10FY2014–2018$2.0M | Integrated Translational Cancer Science Center | API2 | |
| U54CA209997 U54FY2016–2021$21.2M | Structural and Functional Biology-based analysis of non-oncogene cancer dependencies | API | |
| K12CA138464 K12FY2011–2025$11.4M | UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program | API | |
| P30CA093373 P30FY2002–2026$128.2M | Integrated Cancer Biology Program | API | |
| R01CA177684 R01FY2014–2025$3.5M | Strategies for Receptor inhibition in immunotherapy | API | |
| T32CA207021 T32FY2016–2020$2.4M | Cancer Immunology Training Grant | API | |
| U01CA224146 U01FY2017–2021$3.0M | Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens | API | |
| U01CA274276 U01FY2022–2026$5.1M | Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity | API |
Awards that maintain or redistribute this data
Resource and center grants credited on articles that used the data. Kept out of the flow above because they pay for the pipes, not for a cohort or a finding.
| Award | Project | Evidence |
|---|---|---|
| P01CA013106 P01FY1985–2026$269.1M | Project 2: Splicing Dysregulation in Cancer | API |
| P30CA010815 P30FY1985–2026$173.4M | Research Program: Molecular and Cellular Oncogenesis | API |
| P30CA013696 P30FY1985–2026$280.8M | Developmental Funds | API |
| P30CA034196 P30FY1985–2026$123.6M | Cancer Center Support (CORE) Grant | API |
| P30CA045508 P30FY1987–2026$227.8M | Cancer Research Training and Education Coordination Core | API |
| P30CA046592 P30FY1988–2026$317.9M | Cancer Center Administration | API |
| P30CA093373 P30FY2002–2026$128.2M | Integrated Cancer Biology Program | API |
| P50CA101955 P50FY2010–2014$22.2M | UAB / UMN SPORE in Pancreatic Cancer | API |
| U01CA200468 U01FY2016–2026$11.0M | Clinical Validation Center for Early Detection of Pancreatic Cancer | API |
| U01CA224145 U01FY2017–2021$2.6M | Interrupting Cellular Crosstalk in the Immunosuppressive Microenvironment of Pancreas Cancer | API |
| U01CA224146 U01FY2017–2021$3.0M | Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens | API |
| U01CA274154 U01FY2022–2026$4.2M | Fibroblast orchestration of the immune response in pancreatic cancer | API |
| U01CA274276 U01FY2022–2026$5.1M | Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity | API |
| U54CA209997 U54FY2016–2021$21.2M | Structural and Functional Biology-based analysis of non-oncogene cancer dependencies | API |
Where the links come from
NIH RePORTER maps a PMID to the awards that reported it. On a dataset’s marker paper that gives the awards which created it; on an article that used the data, the awards which funded that use.
The two sides are not measured alike. Generation is complete: a dataset has one marker paper and every award on it is resolved. Reuse is a sample - the articles using a dataset can number in the thousands, and only the few dozen strongest are retrieved and looked up. Every award shown here funded reuse; there are more that are not shown.
How far it reaches
283 datasets have an award credited with creating them, 80 with using them, and 31 both.
What is missing
No citable accession means no traceable articles; no authoritative marker paper means no attributable generation award. Absence is a gap in the record. Methods.
Start from an award instead, and see every dataset it touches.